Get started
Author

Neha Korde

OpenAlex ID: A5137140349
OA-57 Predicting Progression in Smoldering Multiple Myeloma: A Dynamic AI Model That Learns From Each Clinical Visit
2026 · Anish K. Simhal, Ross Firestone, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-181 Etentamig in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-Cell Maturation Antigen (BCMA)-Targeted Therapy
2026 · Saurabh Chhabra, Emma Searle, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-125 Cytomegalovirus Reactivation after BCMA CAR TCell Therapy Among Relapsed Refractory Multiple Myeloma Patients
2026 · Darshi Shah, Hamza Hashmi, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-023 ALTITUDE - ALTernating Induction Therapies to achieve Undetectable Disease Endpoints: Ph 1/2 Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-Risk Newly Diagnosed Multiple Myeloma
2026 · Neha Korde, Carlyn Tan, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-133 Deep Generative Modeling of Multi-Cohort Flow Cytometry Reveals a T-Cell Exhaustion Signature Predictive of Post-ASCT Outcomes in Myeloma
2026 · Kevin C. Miller, Anish Simhal, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-009 A Pilot Study of Romosozumab in Postmenopausal Women with Myeloma-related Bone Disease and Osteoporosis
2026 · Carlyn Tan, Andriy Derkach, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-079 Ciltacabtagene Autoleucel as Early versus Late Line of Therapy for Patients with Relapsed Refractory Multiple Myeloma: A Real-World Analysis
2026 · Aytaj Mammadzadeh, Hamza Hashmi, et al. · Clinical Lymphoma Myeloma & Leukemia
Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model
2026 · Theresia Akhlaghi, David Nemirovsky, et al. · HemaSphere
PDF
A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma
2026 · Urvi A. Shah, Andriy Derkach, et al. · Haematologica
Recurrent non-coding mutational hotspots drive chromosomal rearrangement and disease progression in multiple myeloma
2026 · Patrick Blaney, Kylee H. Maclachlan, et al. · Zenodo (CERN European Organization for Nuclear Research)
Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.
2026 · Saurabh Chhabra, Emma Searle, et al. · Journal of Clinical Oncology
Works count: 11
Citation count:
H-index:
I10-index:
Year
Topic
Type